Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prostaglandin E synthase 3 like (PTGES3L) is a predicted protein-coding gene in humans, related to the known PTGES3 gene but described as "putative" or "predicted" with no established enzymatic or receptor activity. PTGES3L is thought to enable Hsp90 protein binding and protein-folding chaperone binding activity, potentially being involved in chaperone-mediated protein complex assembly and protein folding, localizing to the cytoplasm, cytosol, and nucleus. There is no clear evidence of it having prostaglandin E synthase enzymatic activity, nor is it recognized as a validated therapeutic target, receptor, enzyme, or transporter[1][4][8][10]. PTGES3L is a putative, unvalidated protein likely involved in chaperone-mediated processes, not an established therapeutic target, with uncertain biological or pharmacological significance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prostaglandin E synthase 3 like (PTGES3L).